Quantcast
Home > Quotes > ALLK

Allakos Inc. Common Stock (ALLK) Quote & Summary Data

ALLK 
$57.355
*  
1.435
2.57%
Get ALLK Alerts
*Delayed - data as of Nov. 16, 2018 11:56 ET  -  Find a broker to begin trading ALLK now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ALLK Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 56.91 / $ 57.80
1 Year Target
53
Today's High / Low
$ 59.7638 / $ 54.24
Share Volume
124,145
50 Day Avg. Daily Volume
190,155
Previous Close
$ 55.92
52 Week High / Low
$ 61.21 / $ 26
Market Cap
2,415,394,499
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
124,145
50 Day Avg. Daily Volume:
190,155

Trading Range

The current last sale of $57.355 is 120.60% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 59.7638 $ 61.21
 Low: $ 54.24 $ 26

Company Description (as filed with the SEC)

We are a clinical stage biotechnology company developing AK002, our wholly owned monoclonal antibody, for the treatment of various eosinophil and mast cell related diseases. AK002 demonstrated pharmacodynamic activity in both of our completed Phase 1 trials, and in the single ascending dose Phase 1 trial involving patients with indolent systemic mastocytosis ("ISM"), patients reported improvements in their symptoms. AK002 selectively targets both eosinophils and mast cells, which are types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. As such, AK002 has the potential to treat a large number of severe diseases.  ... More ...  


Risk Grade

Where does ALLK fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 55.88
Open Date:
Nov. 16, 2018
Close Price:
$ 55.92
Close Date:
Nov. 15, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x